Abeona Story

<div class='circular--portrait' style='background:#800000;color: #F8F8FF;font-size:4em;'>AT</div>
ABEO -- USA Stock  

USD 1.86  0.09  4.62%

It seems Abeona Therapeutics may not have a good chance to recover from the latest slide as its shares fell again. The company's current daily volatility is 4.6 percent, with a beta of 0.51 and an alpha of 0.28 over DOW. As many millenniums are excited about the latest volatility, it is fair to outline Abeona Therapeutics based on its historical price patterns. We will cover the possibilities of making Abeona Therapeutics into a steady grower in September.
Published over a month ago
View all stories for Abeona Therapeutics | View All Stories
Are Abeona Therapeutics (NASDAQ:ABEO) institutional investors starting to panic?
Abeona Therapeutics currently holds roughly 116.04 M in cash with (60.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.39. We provide trade advice to complement the prevailing expert consensus on Abeona Therapeutics. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
Investing in Abeona Therapeutics, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Abeona Therapeutics along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.

How important is Abeona Therapeutics's Liquidity

Abeona Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Abeona Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Abeona Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Abeona Therapeutics's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Abeona Therapeutics, but it might be worth checking our own buy vs. sell analysis

Abeona Therapeutics Correlation with Peers

Investors in Abeona can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Abeona Therapeutics. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Abeona Therapeutics and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Abeona is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage. Please check volatility of Abeona for more details

Sale by Sco Capital Partners Llc of 1989 shares of Abeona Therapeutics

Legal trades by Abeona Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Abeona insider trading alert for sale of common stock by Sco Capital Partners Llc, the corporate stakeholder, on 17th of September 2020. This event was filed by Abeona Therapeutics Inc with SEC on 2020-09-17. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking it down a bit more

Abeona Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0201, which signifies that the company had -0.0201% of return per unit of standard deviation over the last month. Macroaxis philosophy in foreseeing the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and technical indicators. Abeona Therapeutics exposes twenty-one different technical indicators, which can help you to evaluate volatility that cannot be diversified away. Please be advised to confirm Abeona Therapeutics risk adjusted performance of 0.1219, and Mean Deviation of 4.11 to double-check the risk estimate we provide.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Is Abeona Therapeutics growth reasonable after the slide?

The variance is down to 30.69 as of today. Abeona Therapeutics shows above-average downside volatility for the selected time horizon. We advise investors to inspect Abeona Therapeutics further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Abeona Therapeutics future alpha.

Our Takeaway on Abeona Therapeutics Investment

Whereas many other companies in the biotechnology industry are either recovering or due for a correction, Abeona Therapeutics may not be performing as strong as the other in terms of long-term growth potentials. The inconsistency in the assessment between current Abeona valuation and our trade advice on Abeona Therapeutics is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Abeona Therapeutics.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Abeona Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com